U.S. SECURITIES AND EXCHANGE COMMISSION
                             Washington, D.C. 20549

                                  FORM 10-QSB/A
                                  -------------


(MARK ONE)

[X]  QUARTERLY REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT
     OF 1934 FOR THE QUARTERLY PERIOD ENDED AUGUST 31, 2003

[ ]  TRANSITION REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE
     ACT OF 1934 FOR THE TRANSITION PERIOD FROM          TO
                                               ---------   ------------


COMMISSION FILE NUMBER: 000-26089



                       L.O.M. MEDICAL INTERNATIONAL, INC.
                       ----------------------------------
        (Exact name of small business issuer as specified in its charter)

DELAWARE                                                     98-0178784
--------                                                     ----------
(State or other jurisdiction of                              (I.R.S. Employer
incorporation or organization)                               Identification No.)


                       #3-1482 Springfield Road, Kelowna,
                        British Columbia, Canada V1Y 5V3
                       ----------------------------------
                    (Address of principal executive offices)

                                  250.762.7552
                                  ------------
                (Issuer's Telephone Number, including Area Code)



                              Thomas E. Stepp, Jr.
                                 Stepp Law Group
                          32 Executive Park, Suite 105
                          Irvine, California 92614-6742
                             Telephone: 949.660.9700
                             Facsimile: 949.660.9010
                         -------------------------------
            (Name, Address and Telephone Number of Agent for Service)


                APPLICABLE ONLY TO ISSUERS INVOLVED IN BANKRUPTCY
                   PROCEEDINGS DURING THE PRECEDING FIVE YEARS

Check  whether  the issuer  (1) has filed all  reports  required  to be filed by
Section 13 or 15(d) of the  Exchange  Act during the past 12 months (or for such
shorter period that the  registrant was required to file such reports),  and (2)
has been subject to such filing  requirements for the past 90 days.
                                                                 [x] Yes  [ ] No

                      APPLICABLE ONLY TO CORPORATE ISSUERS

State the number of shares outstanding of each of the issuer's classes of common
equity,  as of the latest  practical  date.  As of August 31,  2003,  there were
6,310,813  shares of the  issuer's  $.001  par value  common  stock  issued  and
outstanding.


<PAGE>








                                     PART I
                                     ------



SPECIAL NOTE REGARDING INDEPENDENT ACCOUNTANTS REVIEW
-----------------------------------------------------
Our independent accountants,  KPMG LLP, have not performed any review procedures
at the time of filing this quarterly  report on Form 10-QSB for the three months
ended August 31, 2003, as required under Item 310(b) of Regulation S-B.



Item 1.  Financial Statements
-----------------------------









                        Consolidated Financial Statements of


                        L.O.M. MEDICAL INTERNATIONAL INC.
                        ---------------------------------

                        (A Development Stage Enterprise)

                        Three months ended August 31, 2003

                        (Unaudited)


























                                       F-1
<PAGE>



<TABLE>
<CAPTION>
L.O.M. MEDICAL INTERNATIONAL INC.
(A Development Stage Enterprise)

Consolidated Balance Sheets
$ United States

August 31, 2003 and May 31, 2003

-----------------------------------------------------------------------------------------------------
                                                                       August 31,             May 31,
                                                                             2003                2003
                                                                      (Unaudited)
-----------------------------------------------------------------------------------------------------

Assets

<S>                                                              <C>                 <C>
Current assets:
     Cash and cash equivalents                                   $        6,536      $        7,642
     Amounts receivable                                                   2,932              16,418
     Prepaid expenses                                                    71,768              71,799
     ------------------------------------------------------------------------------------------------
                                                                         81,236              98,859

Deposits                                                                 11,003              11,117

Property, plant and equipment                                            16,114              17,270

-----------------------------------------------------------------------------------------------------
                                                                 $      108,353      $      124,246
-----------------------------------------------------------------------------------------------------

Liabilities and Stockholders' Deficiency

Current liabilities:
     Accounts payable and accrued liabilities                    $      627,549      $      516,837
     Convertible promissory notes (note 3)                               16,284              46,486
     ------------------------------------------------------------------------------------------------
                                                                        643,833             563,323

Minority interest                                                       318,150             321,469


Share subscriptions (note 4)                                            143,242             100,605

Stockholders' deficiency:
     Capital stock
       5,000,000   preferred shares with a par value of
                   $0.001 per share authorized
       50,000,000  common shares with a par value of
                   $0.001 per share authorized, 6,310,813
                   issued (May 31, 2003 - 6,311,813 issued),
                   net of treasury stock of 52,573 (May 31,
                   2003 - 52,073)                                         6,311               6,312
     Additional paid-in capital                                       4,077,490           4,080,739
     Deficit accumulated during the development stage                (5,113,977)         (4,981,506)
     Accumulated other comprehensive income                              33,304              33,304
     ------------------------------------------------------------------------------------------------
                                                                       (996,872)           (861,151)
Going concern (note 1 (a))
Commitments (note 2 (b))
Contingent liabilities (note 2 (a))
-----------------------------------------------------------------------------------------------------
                                                                 $      108,353      $      124,246
-----------------------------------------------------------------------------------------------------
</TABLE>

See accompanying notes to consolidated financial statements




                                       F-2
<PAGE>



<TABLE>
<CAPTION>
L.O.M. MEDICAL INTERNATIONAL INC.
(A Development Stage Enterprise)

Consolidated Statements of Loss
$ United States

Three months ended August 31, 2003 and 2002 and period from inception (March 17,
1997) to August 31, 2003 (Unaudited)

--------------------------------------------------------------------------------------------------------
                                                  From inception          Three months ended, August 31,
                                                (March 17, 1997)          ------------------------------
                                              to August 31, 2003                2003                2002
--------------------------------------------------------------------------------------------------------

<S>                                           <C>                   <C>                 <C>
Expenses:
     General and administration               $      3,814,519      $      109,574      $      171,892
     Research and development                        1,422,277              22,898              23,103
     ---------------------------------------------------------------------------------------------------
                                                     5,236,796             132,472             194,995

--------------------------------------------------------------------------------------------------------
Loss from operations                                (5,236,796)           (132,472)           (194,995)

Other income:
     Interest income                                   122,819                   1                 274

--------------------------------------------------------------------------------------------------------
Loss                                          $     (5,113,977)     $     (132,471)     $     (194,721)
--------------------------------------------------------------------------------------------------------


Weighted average number of common shares,
   basic and diluted                                 5,248,528           6,311,476           6,181,334


Loss per share, basic and diluted             $          (0.97)     $        (0.02)     $        (0.03)
--------------------------------------------------------------------------------------------------------
</TABLE>

See accompanying notes to consolidated financial statements
























                                       F-3
<PAGE>



<TABLE>
<CAPTION>
L.O.M. MEDICAL INTERNATIONAL INC.
(A Development Stage Enterprise)

Consolidated Statements of Cash Flows
$ United States

Three months ended August 31, 2003 and 2002 and period from inception (March 17,
1997) to August 31, 2003 (Unaudited)

-------------------------------------------------------------------------------------------------------------------------------
                                                                         From inception           Three months ended August 31,
                                                                       (March 17, 1997)           -----------------------------
                                                                     to August 31, 2003                2003                2002
-------------------------------------------------------------------------------------------------------------------------------

Cash flows provided by (used in):

<S>                                                                  <C>                   <C>                 <C>
Operating activities:
   Loss for the period                                               $     (5,113,977)     $     (132,471)     $     (194,721)

   Items not involving cash
     Amortization                                                             102,707               1,156               4,044
     Amortization of discount on convertible promissory notes                  41,034               8,099                   -
     Gain on sale of fixed assets                                              (2,659)                  -                   -
     Write down of product rights and patent costs                            374,128                   -                   -
     Subscription for common shares for consulting services                     1,625                   -              73,659
     Common shares issued for consulting services                             109,584                   -                   -
     Compensation cost of stock options issued for services                   486,719                   -                   -
     Foreign exchange loss (gain) on redeemable preferred shares               16,423              (3,319)             (5,810)
     Write-down of advances and deposits                                      168,680                   -                   -
     Common shares issued in lieu of cash payment of
       Interest on convertible promissory notes                                 1,341               1,086                   -

   Changes in non-cash working capital
     Amounts receivable                                                        (2,932)             13,486              (4,000)
     Prepaid expenses                                                         (71,768)                 31                   -
     Accounts payable and accrued liabilities                                 460,739             109,087             (18,353)
     --------------------------------------------------------------------------------------------------------------------------
                                                                           (3,428,356)             (2,845)           (145,181)
Financing activities:
     Issuance of capital stock                                              2,746,747                   -                   -
     Issuance of convertible debentures                                        72,639                   -                   -
     Common shares rescinded or repurchased                                   (48,851)             (1,625)                  -
     Proceeds from subscriptions for shares                                   999,299               3,250             150,525
     --------------------------------------------------------------------------------------------------------------------------
                                                                            3,769,834               1,625             150,525
Investing activities:
     Deposits                                                                (179,683)                114                   -
     Proceeds on disposition of property, plant and equipment                   6,189                   -                   -
     Acquisition of property, plant and equipment                            (104,352)                  -                   -
     Acquisition of product rights                                            (90,577)                  -                   -
     --------------------------------------------------------------------------------------------------------------------------
                                                                             (368,423)                114                   -

Effects of change in exchange rates on cash                                    33,481                   -                   -
-------------------------------------------------------------------------------------------------------------------------------
Increase (decrease) in cash                                                     6,536              (1,106)              5,344

Cash, beginning of period                                                           -               7,642             142,114
-------------------------------------------------------------------------------------------------------------------------------
Cash, end of period                                                  $          6,536      $        6,536      $      147,458
-------------------------------------------------------------------------------------------------------------------------------







                                       F-4
<PAGE>


<CAPTION>
L.O.M. MEDICAL INTERNATIONAL INC.
(A Development Stage Enterprise)

Consolidated Statements of Cash Flows (continued)
$ United States

Three months ended August 31, 2003 and 2002 and period from inception (March 17,
1997) to August 31, 2003 (Unaudited)

-------------------------------------------------------------------------------------------------------------------------------

<S>                                                                  <C>                   <C>                 <C>
Supplementary information
   Interest paid                                                     $              -      $            -      $            -
   Income taxes paid                                                                -                   -                   -
Non-cash financing and investing activities
   Issuance of redeemable preferred shares for product rights                 309,677                   -                   -
   Common shares issued for conversion of share subscriptions                 909,719                   -               6,800
   Common shares issued for consulting services                               109,584                   -                   -
   Common shares rescinded and cancelled                                       47,851               1,625                   -
   Subscriptions for common shares for consulting services                      1,625                   -                   -
   Common shares issued upon conversion of convertible promissory
     notes and accrued interest                                                 1,293                   -                   -
   Subscriptions for common shares upon conversion of convertible
     promissory notes and accrued interest                                     52,037              39,387                   -
   Compensation cost of stock options issued for services                     486,719                   -                   -
   Unpaid amount related to rescinded shares (note 2 (a))                     156,709              (1,625)                  -
   Unpaid amount related to returned shares                                    10,101               3,250                   -
-------------------------------------------------------------------------------------------------------------------------------
</TABLE>

See accompanying notes to consolidated financial statements




























                                       F-5
<PAGE>



<TABLE>
<CAPTION>
L.O.M. MEDICAL INTERNATIONAL INC.
(A Development Stage Enterprise)

Consolidated  Statement of Stockholders'  Equity  (Deficiency) and Comprehensive
Loss
$ United States

Period from inception (March 17, 1997) to August 31, 2003

-----------------------------------------------------------------------------------------------------------------------------
                                               Capital Stock                          Deficit
                                          -----------------------                 Accumulated     Accumulated           Total
                                             Number                  Additional    During the           Other   Stockholders'
                                          of Common                     Paid in   Development   Comprehensive          Equity
                                             Shares        Amount       Capital         Stage          Income    (Deficiency)
-----------------------------------------------------------------------------------------------------------------------------

<S>                                      <C>         <C>           <C>           <C>           <C>             <C>
Common shares issued on incorporation            3   $         1   $         -    $        -   $           -   $           1

Comprehensive income (loss):
  Loss                                           -             -             -      (138,272)              -        (138,272)
  Foreign currency translation                   -             -             -             -          13,582          13,582
-----------------------------------------------------------------------------------------------------------------------------
Comprehensive loss                                                                                                  (124,690)

-----------------------------------------------------------------------------------------------------------------------------
Balance, May 31, 1997                            3             1             -      (138,272)         13,582        (124,689)

Common shares issued to founders
  and others at $0.001                   4,210,090         4,210             -             -               -           4,210

Common shares issued at $1.00
  net of share issue costs                 668,154           668       469,887             -               -         470,555

Common shares issued at $1.00 on
  conversion of share subscriptions        605,000           605       604,395             -               -         605,000

Comprehensive income (loss):
  Loss                                           -             -             -      (293,239)              -        (293,239)
  Foreign currency translation                   -             -             -             -          (7,294)         (7,294)
-----------------------------------------------------------------------------------------------------------------------------
Comprehensive loss                                                                                                  (300,533)

-----------------------------------------------------------------------------------------------------------------------------
Balance, May 31, 1998                    5,483,247         5,484     1,074,282      (431,511)          6,288         654,543

Common shares issued on
  November 30, 1998 at $3.25
  net of share issue costs                  36,300            36        96,726             -               -          96,762

Comprehensive income (loss):
  Loss                                           -             -             -      (726,055)              -        (726,055)
  Foreign currency translation                   -             -             -             -          17,038          17,038
-----------------------------------------------------------------------------------------------------------------------------
Comprehensive loss                                                                                                  (709,017)

-----------------------------------------------------------------------------------------------------------------------------
Balance, May 31, 1999                    5,519,547         5,520     1,171,008    (1,157,566)         23,326          42,288

Common shares issued on
  April 17, 2000 at $3.25
  net of share issue costs                 307,610           308       967,335             -               -         967,643

Common shares issued on
  May 10, 2000 at $3.25 on
  conversion of share
  subscriptions                             19,302            19        62,712             -               -          62,731

Comprehensive income (loss):
  Loss                                           -             -             -      (508,835)              -        (508,835)
  Foreign currency translation                   -             -             -             -           9,978           9,978
-----------------------------------------------------------------------------------------------------------------------------
Comprehensive loss                                                                                                  (498,857)

-----------------------------------------------------------------------------------------------------------------------------

Balance, May 31, 2000                    5,846,459   $     5,847   $ 2,201,055   $(1,666,401)  $      33,304   $     573,805
-----------------------------------------------------------------------------------------------------------------------------




                                       F-6
<PAGE>



<CAPTION>
L.O.M. MEDICAL INTERNATIONAL INC.
(A Development Stage Enterprise)

Consolidated  Statements of Stockholders'  Equity (Deficiency) and Comprehensive
Loss (continued)
$ United States

Period from inception (March 17, 1997) to August 31, 2003

-----------------------------------------------------------------------------------------------------------------------------
                                               Capital Stock                          Deficit
                                          -----------------------                 Accumulated     Accumulated           Total
                                             Number                  Additional    During the           Other   Stockholders'
                                          of Common                     Paid in   Development   Comprehensive          Equity
                                             Shares        Amount       Capital         Stage          Income    (Deficiency)
-----------------------------------------------------------------------------------------------------------------------------

<S>                                      <C>         <C>           <C>           <C>           <C>             <C>
Balance, May 31, 2000,
  carried forward                        5,846,459   $     5,847   $ 2,201,055   $(1,666,401)  $      33,304   $     573,805

Common shares issued on
  September 22, 2000 for
  cash at $3.25 net of share
  issue costs                              249,271           250       726,654             -               -         726,904

Common shares issued on
  December 19, 2000 at $3.25
  on conversion of share
  subscriptions                             57,081            57       185,456             -               -         185,513

Compensation costs for
  stock options issued for
  services                                       -             -       295,269             -               -         295,269

Comprehensive income (loss):
  Loss                                           -             -             -    (1,216,128)              -      (1,216,128)
  Foreign currency translation                   -             -             -             -               -               -
-----------------------------------------------------------------------------------------------------------------------------
Comprehensive loss                                                                                                (1,216,128)

-----------------------------------------------------------------------------------------------------------------------------

Balance, May 31, 2001                    6,152,811   $     6,154   $ 3,408,434   $(2,882,529)  $      33,304   $     565,363

Common shares issued on
  August 31, 2001 at $3.25
  on conversion of share
  subscriptions                              6,800             7        22,093             -               -          22,100

Common shares issued for cash
  on October 11, 2001 at $3.25, net
  of share issue costs                      38,211            38       110,245             -               -         110,283

Common shares issued for cash
  on January 10, 2002 at $3.25               5,020             5        16,310             -               -          16,315

Common shares issued for cash
  on January 10, 2002 at $2.41              47,697            47       114,903             -               -         114,950

Common shares issued for consulting
  services rendered on January 10,
  2002 at $2.41                              7,303             7        17,593             -               -          17,600

Shares rescinded and cancelled
  on February 22, 2002                     (18,702)          (19)      (46,207)            -               -         (46,226)

Common shares issued for cash
  on April 2, 2002 at $3.25                  2,880             3         9,357             -               -           9,360

Common shares issued for cash
  on April 2, 2002 at $2.41                 10,400            10        25,054             -               -          25,064



                                       F-7
<PAGE>



<CAPTION>
L.O.M. MEDICAL INTERNATIONAL INC.
(A Development Stage Enterprise)

Consolidated  Statements of Stockholders'  Equity (Deficiency) and Comprehensive
Loss (continued)
$ United States

Period from inception (March 17, 1997) to August 31, 2003

-----------------------------------------------------------------------------------------------------------------------------
                                               Capital Stock                          Deficit
                                          -----------------------                 Accumulated     Accumulated           Total
                                             Number                  Additional    During the           Other   Stockholders'
                                          of Common                     Paid in   Development   Comprehensive          Equity
                                             Shares        Amount       Capital         Stage          Income    (Deficiency)
-----------------------------------------------------------------------------------------------------------------------------

<S>                                      <C>         <C>           <C>           <C>           <C>             <C>
Common shares issued for cash
  on April 2, 2002 at $1.00                 10,000            10         9,990             -               -          10,000

Common shares issued for cash
  on April 24, 2002 at $3.25                   462             1         1,501             -               -           1,502

Comprehensive loss                               -             -             -    (1,051,699)              -      (1,051,699)
-----------------------------------------------------------------------------------------------------------------------------
                                         6,262,882         6,263     3,689,273    (3,934,228)         33,304        (205,388)

Shares rescinded and retained
  as treasury stock                        (81,231)          (81)     (217,266)            -               -        (217,347)

Shares repurchased and retained
  as treasury stock                         (3,205)           (3)       (7,848)            -               -          (7,851)

-----------------------------------------------------------------------------------------------------------------------------
Balance, May 31, 2002                    6,178,446   $     6,179   $ 3,464,159   $(3,934,228)  $      33,304   $    (430,586)

Common shares issued on conversion
  on share subscriptions on
  August 30, 2002 at $3.25, net
  of share issue costs                      10,693            11        34,364             -               -          34,375

Common shares issued for cash on
  October 29, 2002 at $2.485                   165             -           410             -               -             410

Common shares issued for cash on
  October 29, 2002 at $2.61, net
  of share issue costs                      16,935            17        44,183             -               -          44,200

Common shares issued for cash on
  October 29, 2002 at $2.70, net
  of share issue costs                      14,923            15        40,275             -               -          40,290

Common shares issued for cash on
  October 29, 2002 at $3.25                    500             -         1,625             -               -           1,625

Common shares issued for cash on
  October 29, 2002 at $4.40                 14,546            15        63,985             -               -          64,000

Common shares issued for consulting
  services on October 29, 2002 at $3.09     23,827            24        73,636             -               -          73,660

Common shares issued for cash on
  February 28, 2003 at $3.25                11,630            12        37,786             -               -          37,798

Common shares issued for consulting
  services on February 28, 2003 at $3.25     4,638             5        15,069             -               -          15,074




                                       F-8
<PAGE>



<CAPTION>
L.O.M. MEDICAL INTERNATIONAL INC.
(A Development Stage Enterprise)

Consolidated  Statements of Stockholders'  Equity (Deficiency) and Comprehensive
Loss (continued)
$ United States

Period from inception (March 17, 1997) to August 31, 2003

-----------------------------------------------------------------------------------------------------------------------------
                                               Capital Stock                          Deficit
                                          -----------------------                 Accumulated     Accumulated           Total
                                             Number                  Additional    During the           Other   Stockholders'
                                          of Common                     Paid in   Development   Comprehensive          Equity
                                             Shares        Amount       Capital         Stage          Income    (Deficiency)
-----------------------------------------------------------------------------------------------------------------------------

<S>                                      <C>         <C>           <C>           <C>           <C>             <C>
Common shares issued on
  February 28, 2003 at $2.00 upon
  conversion of convertible promissory
  note                                         323             -           646             -               -             646

Common shares issued for cash
  on May 20, 2003 at $3.25                   1,500             1         4,874             -               -           4,875

Common shares issued on
  May 20, 2003 at $2.00 upon
  conversion of convertible promissory
  note                                         324             -           647             -               -             647

Common shares issued for consulting
  services on May 20, 2003 at $3.25          1,000             1         3,249             -               -           3,250

Share rescission retracted (note 5(a))      32,363            32        58,981             -               -          59,013

Beneficial conversion option on
  convertible promissory notes (note 6)          -             -        45,400             -               -          45,400

Compensation cost of options issued
  for services (note 8 (b))                      -             -       191,450             -               -         191,450

Comprehensive loss:
  Loss                                           -             -             -    (1,047,278)              -      (1,047,278)
-----------------------------------------------------------------------------------------------------------------------------
Balance, May 31, 2003                    6,311,813   $     6,312   $ 4,080,739   $(4,981,506)  $      33,304   $    (861,151)

Shares repurchased and retained
  as treasury stock                         (1,000)           (1)       (3,249)            -               -          (3,250)

Comprehensive loss:
  Loss                                           -             -             -      (132,471)              -        (132,471)
-----------------------------------------------------------------------------------------------------------------------------
Balance, August 31, 2003                 6,310,813   $     6,311   $ 4,077,490   $(5,113,977)  $      33,304   $    (996,872)
=============================================================================================================================
</TABLE>













                                       F-9
<PAGE>



L.O.M. MEDICAL INTERNATIONAL INC.
(A Development Stage Enterprise)

Notes to Consolidated Financial Statements
$ United States

Three months ended August 31, 2003 and 2002
(Unaudited)

--------------------------------------------------------------------------------


L.O.M.  Medical  International Inc. was incorporated on March 17, 1997 under the
General  Corporation Laws of Delaware.  It conducts  research and development on
new products in the medical field  including a retractable  syringe.  Operations
effectively commenced on June 1, 1997.

1.   Significant accounting policies:
-------------------------------------

     a)   Going concern

          These  financial  statements  have been  prepared by management on the
          going concern basis in accordance with accounting principles generally
          accepted  in  the  United   States  of  America,   which  assumes  the
          realization of assets and  liquidation of liabilities  and commitments
          in the  normal  course  of  business.  As  shown  in the  consolidated
          financial statements,  to date, the Company has generated no revenues,
          has a working  capital  deficiency and has accumulated a deficit since
          inception  of   $5,113,977.   These  factors,   among  others,   raise
          substantial  doubt about the Company's  ability to continue as a going
          concern.  The  Company's  ability to  continue  as a going  concern is
          dependent on its ability to generate future profitable  operations and
          receive  continued  financial  support from its stockholders and other
          investors.  The consolidated  financial  statements do not include any
          adjustments that might result from the outcome of this uncertainty.

          In the short-term,  management's  plans involve  obtaining  additional
          funding   from   stockholders   in  the  form  of   additional   share
          subscriptions  to support  continued  operations.  In the longer term,
          management's  plans include  generating future  profitable  operations
          from  future  sales  of  the  retractable  syringe.  There  can  be no
          assurance  that a market will develop for the  retractable  syringe or
          that additional share financings will be available.  Failure to obtain
          adequate  financing to continue  current  development  activities will
          cause the Company to curtail operations.

     b)   Basis of presentation

          The  consolidated  financial  statements  include the  accounts of the
          Company and its wholly owned subsidiary. All significant inter-company
          balances and transactions have been eliminated.

          The  financial  information  presented as at August 31, 2003,  for the
          three  months  ended  August 31, 2003 and 2002 and for the period from
          inception  (March 17, 1997) to August 31, 2003 is unaudited,  however,
          in the opinion of management,  all adjustments  (consisting  solely of
          normal recurring  items) necessary for the fair  presentation of these
          unaudited amounts in conformity with accounting  principles  generally
          accepted  in the  United  States  of  America  have been  made.  These
          unaudited interim consolidated  financial statements should be read in
          conjunction with the annual consolidated  financial statements for the
          year ended May 31, 2003 filed under Form 10-KSB.

     c)   Management estimates

          The preparation of financial  statements in conformity with accounting
          principles generally accepted in the United States of America requires
          management to make estimates and assumptions  that affect the reported
          amounts of assets and liabilities and disclosures of contingent assets
          and  liabilities  at the  date  of the  financial  statements  and the
          reported amounts of revenues and expenses during the reporting period.
          Actual results could differ from those estimates.




                                      F-10
<PAGE>


L.O.M. MEDICAL INTERNATIONAL INC.
(A Development Stage Enterprise)

Notes to Consolidated Financial Statements
$ United States

Three months ended August 31, 2003 and 2002
(Unaudited)

--------------------------------------------------------------------------------


2.   Contingent liability:
--------------------------

     (a)  Stockholders  who  acquired  99,933 of common  stock from the  Company
          prior  to  May  31,  2001  for  aggregate  proceeds  of  approximately
          $263,573,  exercised  their right of rescission  during the year ended
          May 31, 2002. As of August 31, 2003 the Company has repaid  $47,851 of
          the  $263,573.  The  remaining  $156,709  as at  August  31,  2003  is
          unsecured and is included in accounts payable and accrued  liabilities
          on  the  consolidated   balance  sheet.  The  Company  does  not  have
          sufficient funds to repay this liability at this time.

          Treasury   stock  consists  of  the  99,933  shares  of  common  stock
          originally  acquired under the rescission  order less 19,202 shares of
          common stock that was  cancelled and 32,363 shares of common stock for
          which the  rescission  offer was  retracted by the original  purchaser
          plus 4,205 shares which were repurchased separately and are being held
          as treasury stock for total treasury stock of 52,573 shares.

     (b)  During  the year  ended  the  Company  signed  an  offer  to  purchase
          additional  office  space for  approximately  $604,000  with a planned
          occupancy  date of April 1, 2003. To date, the Company has not secured
          the necessary financing to fund this acquisition.  It is not currently
          the  intention  of the Company to  complete  this  transaction.  It is
          management's best estimate that no liability will arise to the Company
          as a result of not completing this offer to purchase, as another party
          has purchased the intended office space. As a result, no liability has
          been  accrued for this  contingency  in these  consolidated  financial
          statements.

3.   Convertible promissory notes:
----------------------------------

     During  the  year  ended  May 31,  2003,  the  Company  issued  convertible
     promissory  notes for aggregate cash proceeds of $72,639.  The  convertible
     promissory notes bear interest at 7.25%, are unsecured and are due June 30,
     2003.  The original  principal of the notes is convertible to common shares
     at $2.00  per  share.  Accrued  and  unpaid  interest  on the notes was not
     originally convertible to common shares, however subsequent to the issuance
     of the notes  management  and the note holders agreed to convert any unpaid
     interest at the conversion date at $2.00 per share as well.

     A  deemed  discount  existed  at the  date  of  issue  of  the  convertible
     promissory notes due to a beneficial  conversion  option, as the notes were
     convertible into common shares at a price that was less than the fair value
     of the  common  shares  at the  date of  issuance.  Accordingly,  a  deemed
     discount  relating  to the  beneficial  conversion  option of  $45,400  was
     recorded and is being  amortized  over the period from the issuance date to
     the  maturity  date of June 30,  2003 in  accordance  with  issue 6 of EITF
     00-27.

     During the three months ended August 31, 2003,  $38,301 of the  convertible
     promissory  notes plus accrued  interest were converted into  subscriptions
     for 19,697 common shares of the Company.

     ---------------------------------------------------------------------------
     Convertible promissory notes                                     $  20,650

     Unamortized discount related to the beneficial conversion
     option                                                              (4,366)

     ---------------------------------------------------------------------------
                                                                      $  16,284
     ---------------------------------------------------------------------------


                                      F-11
<PAGE>


L.O.M. MEDICAL INTERNATIONAL INC.
(A Development Stage Enterprise)

Notes to Consolidated Financial Statements
$ United States

Three months ended August 31, 2003 and 2002
(Unaudited)

--------------------------------------------------------------------------------


4.   Share subscriptions:
-------------------------

     As at May 31, 2003, the Company had received share subscriptions for 11,337
     common shares at $3.25 per share for net proceeds of $36,845, 19,394 common
     shares at $2.50 per share for net proceeds of $48,485, 455 common shares at
     $2.20 per share for net proceeds of $1,000,  500 common  shares in exchange
     for services  received  prior to May 31, 2003 having a value of $1,625,  as
     well as 6,325 shares at a price of $2.00 per share upon receipt of a notice
     of conversion for a convertible  promissory  note plus interest of $12,650.
     During  the three  months  ended  August 31,  2003,  the  Company  received
     additional share  subscriptions  for 1,000 common shares at $3.25 per share
     for net  proceeds of $3,250,  as well as 19,697  shares at a price of $2.00
     upon receipt of a notice of conversion  for a convertible  promissory  note
     plus interest of $39,387.  All  subscription  proceeds were received by the
     Company  prior to August 31, 2003 and were issued  subsequent to August 31,
     2003.
































                                      F-12
<PAGE>


Item 2.  Management's Discussion and Analysis or Plan of Operation
------------------------------------------------------------------

OUR DISCLOSURE AND ANALYSIS IN THIS REPORT CONTAINS  FORWARD-LOOKING  STATEMENTS
OF OUR MANAGEMENT ("FORWARD-LOOKING  STATEMENTS") INCLUDING, WITHOUT LIMITATION,
FORWARD-LOOKING STATEMENTS REGARDING OUR EXPECTATIONS,  BELIEFS,  INTENTIONS AND
FUTURE STRATEGIES.  FORWARD-LOOKING  STATEMENTS ARE STATEMENTS THAT ESTIMATE THE
HAPPENING   OF  FUTURE   EVENTS   AND  ARE  NOT  BASED  ON   HISTORICAL   FACTS.
FORWARD-LOOKING  STATEMENTS  MAY BE  IDENTIFIED  BY THE  USE OF  FORWARD-LOOKING
TERMINOLOGY,  SUCH AS "COULD",  "MAY", "WILL",  "EXPECT",  "SHALL",  "ESTIMATE",
"ANTICIPATE",  "PROBABLE", "POSSIBLE", "SHOULD", "CONTINUE", "INTEND" OR SIMILAR
TERMS,   VARIATIONS  OF  THOSE  TERMS  OR  THE  NEGATIVE  OF  THOSE  TERMS.  THE
FORWARD-LOOKING  STATEMENTS  SPECIFIED IN THIS  QUARTERLY  REPORT FOR THE 10-QSB
HAVE BEEN COMPILED BY US ON THE BASIS OF  ASSUMPTIONS  MADE BY US AND CONSIDERED
BY US TO BE REASONABLE. OUR FUTURE OPERATING RESULTS, HOWEVER, ARE IMPOSSIBLE TO
PREDICT AND NO  REPRESENTATION,  GUARANTY,  OR  WARRANTY IS TO BE INFERRED  FROM
THOSE FORWARD-LOOKING STATEMENTS.

THE ASSUMPTIONS USED FOR PURPOSES OF THE  FORWARD-LOOKING  STATEMENTS  REPRESENT
ESTIMATES OF FUTURE EVENTS AND ARE SUBJECT TO UNCERTAINTY AS TO POSSIBLE CHANGES
IN ECONOMIC,  LEGISLATIVE,  INDUSTRY, AND OTHER CIRCUMSTANCES.  AS A RESULT, THE
IDENTIFICATION AND INTERPRETATION OF DATA AND OTHER INFORMATION AND THEIR USE IN
DEVELOPING  AND SELECTING  ASSUMPTIONS  FROM AND AMONG  REASONABLE  ALTERNATIVES
REQUIRE THE EXERCISE OF JUDGMENT.  TO THE EXTENT THAT THE ASSUMED  EVENTS DO NOT
OCCUR, THE OUTCOME MAY VARY SUBSTANTIALLY FROM ANTICIPATED OR PROJECTED RESULTS,
AND,  ACCORDINGLY,  NO  OPINION  IS  EXPRESSED  ON THE  ACHIEVABILITY  OF  THOSE
FORWARD-LOOKING   STATEMENTS.  NO  ASSURANCE  CAN  BE  GIVEN  THAT  ANY  OF  THE
ASSUMPTIONS RELATING TO THE FORWARD-LOOKING  STATEMENTS SPECIFIED IN THIS REPORT
ARE ACCURATE,  AND WE ASSUME NO  OBLIGATION  TO UPDATE ANY SUCH  FORWARD-LOOKING
STATEMENTS.

Our Development
---------------

L.O.M.  Medical  International Inc. was incorporated in the State of Delaware on
March 17, 1997. Our executive  offices are located at #3-1482  Springfield Road,
Kelowna, B. C., Canada V1Y 5V3. Our telephone number is 250.762.7552.

For purposes of  clarification,  all dollar amounts  specified in this Quarterly
Report on Form  10-QSB are in the  currency  of the United  States.  Anytime the
symbol "CDN" is used, it refers to the currency of Canada.

Our Business
------------

We were  incorporated for the purpose of researching and developing  health care
products.  Our goal is to become an  innovator  and  provider  of a  retractable
syringe  ("Syringe")  and related  products and  technologies to the health care
market.  We have  successfully  patented and  licensed  products in 70 countries
including the United States and Canada and continue to maintain  these  patents.
We plan to develop  new and  improved  products  and  provide  the  health  care
industry with better, safer products throughout the world.

The Retractable Syringe.
------------------------

We believe the Syringe will change standard  disposal methods for used syringes.
The Syringe has been  developed  to function as a standard  hypodermic  syringe,
which we believe is safer to the  caregiver  or health care  worker.  We believe
that the  Syringe's  unique  design will allow  health care  providers  to avoid
direct contact with used needles. The Syringe is covered by United States Patent
No. 5,868,713, dated February 9, 1999, and international patents have been filed
in 84 different countries.



                                        2
<PAGE>




Once the needle of the  Syringe is  injected,  the user  simply has to press the
plunger  top gently  with his or her thumb to  automatically  retract the needle
into its own sealed chamber. The needle is now hidden where it remains locked in
place and cannot be used  again.  Unlike  other  safety  syringes,  the  plunger
remains inside the barrel of the syringe and requires no hand manipulation.  The
Syringe  will  be  produced  in  standard  industry  sizes  from  1CC  to 20 CC,
inclusive.

We intend to promote  the Syringe as a safer and less  risk-oriented  instrument
for hospital  staff and health care  workers.  We are  optimistic  that doctors,
nurses,  and other health care workers will  recognize and appreciate the safety
features of the Syringe because of its ease of "use-and-disposal" and its unique
"contaminate-prevention" characteristics. We currently have no contracts to sell
the Syringe and there are no guarantees  as to the timing of any such  contracts
in the future.

It is  anticipated  that the products and  technologies  that we develop will be
offered to distributors on a worldwide basis, with an initial emphasis in Canada
and the United States. It is hoped that new product and technology ideas will be
generated  through  active  dialogues  among our  potential  customers,  and our
network of  scientific  advisors.  We also hope to  participate  in national and
international  conferences,  and to  generate  reviews  in  selected  scientific
literature.

Management  interacts with a network of scientific advisors within the industry,
including members of academic institutions,  as well as potential customers.  We
anticipate that these  relationships  will enable us to identify the specialized
needs of those potential  customers,  and to provide innovative and commercially
acceptable  products  and  technologies.  At this time,  our  relationship  with
scientific   advisors   and  academic   institutions   is  limited  to  advisory
relationships.  We  currently  have no  contracts  for testing the Syringe  with
teaching universities and there is a risk that such testing arrangements may not
occur.

Our engineering  personnel are continuing the additional patenting of the L.O.M.
retractable syringe. We are ensuring that patents correctly protect every detail
pertaining  to the  Syringe.  The  detailed  patenting  will  also  include  the
retraction  technology,  and  any  other  medical  device  that  the  retraction
technology incorporates.

Additional  testing  and  refining  of the 3cc  syringe  have led to  additional
enhancements to the Syringe. These enhancements have led to the reduction of the
length,  and the reduced complexity of the various parts.  Initially,  this task
was to eliminate any dead space in the Syringe.  This proved to be successful as
well as enhanced  performance of the retraction  process. It also simplifies the
manufacturing and reduces  production costs. The Syringe now has the same length
and diameter as a conventional syringe, which is a requirement for the end user.
The production molds will be modified for these size changes. The designs of the
..5cc, 1cc, 1.5cc, 5cc and the 10cc are ready for  prototyping.  The final design
enhancements of the 3cc syringe have been incorporated into the 1cc design. With
the 1cc  being  considerably  smaller  than the  3cc,  the  tolerances  are much
tighter.  The extra  engineering  during computer  modeling of component  sizing
ensures that the 1cc syringe performs as well as the 3cc. The extensive  designs
of the syringe  components  have utilized the shared parts between all sizes and
combined the number of parts on a single unit, thus minimizing overall costs.

The Company has begun design  plans for an assembly  line to produce the Syringe
in commercial quantities.  The plan is being developed jointly by management and
a consulting  engineer.  The assembly  line plan  contemplates  features such as
programmable robotic systems with machine vision technology and high-speed parts
flexible feeder systems.  The Company is also  contemplating  injector  moulding
machines,  sterilization  units,  packaging  equipment and other components that
comprise  the  planned  assembly  line.  Such  plans  are  contingent  upon  the
availability of funding. There can be no assurance that the Company will be able
to access sufficient or suitable funding to complete its plans.

During  the  next  12  months  we  anticipate   increasing   our  staff  as  the
pre-production  of the  Syringe  moves  forward.  Dr.  Simon  Wood has agreed to
supervise our research and development department.  Currently, he bills us on an
hourly basis for work completed.  There is no written  contract with him at this
time. We have  contracted  with Kevin Conway,  a mid-level  engineer for certain
services.  Mr.  Conway  performs  subcontract  work on an  hourly  basis.  He is
assisting with the design, engineering, and modeling of the retractable syringe.

We are not currently  producing  commercial  quantities of products or currently
supplying any services to any third  parties.  No assurance can be given that we



                                        3
<PAGE>



will,  on a timely  basis,  be able to make the  transition  from  manufacturing
testing   quantities  of  the  Syringe  to  commercial   production   quantities
successfully or be able to arrange for contract manufacturing.

We anticipate subcontracting the first two years of commercial production of the
Syringe. At the end of the second year of production,  we anticipate engaging in
significant  discussions regarding the potential for the construction of our own
production facility. We recognize that the construction of a production facility
will be contingent  upon us having  reached our sales,  profit  projections  and
financing requirements.

The Blood Collection System
---------------------------

We have  incorporated the retraction  technology into blood collection kits. The
L.O.M. blood collection kit includes the holder,  retractable  needle, gas cell,
and the  retraction  technology.  The Company has also  designed a winged  blood
collection retractable needle. The L.O.M. blood collection tubes complement both
of these systems.

By using  either of these two systems,  the user is able to deliver  exceptional
patient care without  compromising  personal safety. The use of the L.O.M. blood
collection  system  requires  very  little  training  as it looks and feels like
conventional  systems and only requires the  retraction  technology to be easily
activated after the collection is complete. In both systems, the needle retracts
completely  into the unit and is locked while the user is  completely  protected
from needle stick injuries.

Patents for the L.O.M.  blood  collection  kits are  currently  being filed.  We
expect to commence the prototyping phase shortly.

The Eye Care System.
--------------------

We have  invented  and  developed an  insertion  and storage  device for contact
lenses  (the "Eye Care  System"),  which is a method of handling  and  inserting
contact lenses.

We have produced 33,000 units of our eye care inserters,  which will be used for
demonstrations.  As such, we have not inventoried the units but we have expensed
them in the past financial statements as net realizable value (anticipated to be
nil). We currently  have the ability to  subcontract  out for the  production of
commercial  quantities of our eye care products.  We currently have dies with an
output  capacity of 150,000  units.  There is a second set of dies designed that
will have a 300,000 unit capacity which would allow the production of a total of
450,000 units of eye care products per month.

We have FDA  approval  to market  our line of eye care  products  in the  United
States and have the necessary  Canadian  approval to market eye-care products in
Canada.  We are reviewing various contracts with third parties to market the Eye
Care System in Canada as well as the United States.

We plan to focus our  activities  over the next twelve months on the  production
and introduction of the Syringe.  When that is finalized,  we will implement our
marketing plan for the Eye Care System products.

Skin Care Products.
-------------------

At this time we are reorganizing our approach to the skin care line. We will not
be pursuing this area  aggressively  until we have our Syringe  production under
way.

Genetic Patents.
----------------

We are currently  negotiating  licensing  agreements  with the owners of various
patents on genetic vectors.  As of May 31, 2003, we have advanced $54,680 to the
patent owners.  Given the  uncertainty  regarding the future  recoverability  of
these advances we wrote these advances off in our 2002 fiscal year.




                                        4
<PAGE>



Business of Our Subsidiary
--------------------------

There has been no activity in the subsidiary  this quarter.  For the foreseeable
future the subsidiary will be inactive.

Future Capital Requirements
---------------------------

We still require additional cash to implement our business strategies, including
cash for payment of increased  operating  expenses and our existing  obligations
and  commitments.  No  assurance  can be given  that we will have  access to the
capital markets in the future, or that financing will be available on acceptable
terms to satisfy our cash  requirements  necessary  to  implement  the  business
strategies.  The  inability to access the capital  markets or obtain  acceptable
financing could have a material  adverse effect on our results of operations and
financial condition.

Our forecast of the period of time during which our financial  resources will be
adequate to support our operations is a forward-looking  statement that involves
risks and  uncertainties,  and actual results could vary as a result of a number
of factors.

We will have to raise  additional  capital during the next three months in order
to develop,  promote,  produce and distribute  our proposed  products as well as
satisfy our existing obligations, including the liability disclosed in note 2 to
the  financial  statements.  Such  additional  capital  may  be  raised  through
additional  public  or  private  financings,  as well as  borrowings  and  other
resources.  To the extent that additional  capital is raised through the sale of
equity or  equity-related  securities,  the  issuance of such  securities  could
result in dilution of the stockholders.

There can be no assurance that additional funding will be available on favorable
terms,  if at all. If  adequate  funds are not  available  within the next three
months,  we will be required to curtail  operations  significantly  or to obtain
funds through entering into arrangements with  collaborative  partners or others
that may  require us to  relinquish  rights to certain of our  products  that we
would not otherwise relinquish.

The management's report on our August 31, 2003 consolidated financial statements
includes a paragraph  explaining  that we have  generated  no  revenues,  have a
working  capital  deficiency  and  accumulated  a  deficit  since  inception  of
$5,113,977 which are factors,  among others,  that raise substantial doubt about
our ability to continue as a going  concern.  The  financial  statements  do not
include any adjustments that might result from the outcome of this uncertainty

Business Risks
--------------

We are exposed to a variety of business risks, some of which are inherent to all
competitive commercial enterprises,  and others that are specific to the medical
products  industry.  We will  continue to endeavor  to limit all  specific  risk
factors by our operations and financial strategies.

Financial Risks
---------------

Our business  plans are  aggressive in nature.  Continued  rapid  expansion will
consume valuable working capital and result in significant  demand for cash from
operations  during  the next few  quarters.  We  expect  that  existing  capital
resources  and  contributions  from profits will not be  sufficient  to fund our
business plans as represented  without receiving  additional funds from external
sources.

Business Cycles and Risks of Cost Overruns
------------------------------------------

The  sale  and  implementation  of our  products  involve  a  reasonable  market
penetration.  Failure to secure reasonable market penetration could have adverse
effects on our business, results of operations and its financial condition.



                                        5
<PAGE>



Fluctuations in Financial Results
---------------------------------

Our operating  results will  fluctuate,  depending on factors such as the demand
for products,  the size and timing of contracts,  new products and enhancements,
price  competition,  changes in  operating  expenses and  personnel  and general
economic factors.  Therefore,  actual financial  results may vary  significantly
from those projected by us.

Third-Party Claims for Infringement
-----------------------------------

We are not aware that any of our products infringe on the proprietary  rights of
third parties.  There can be no assurance,  however, that third parties will not
claim such  infringements by us with respect to current or future products.  Any
such claims,  with or without merit,  could be time consuming,  result in costly
litigation, or cause product or shipment delays. Any of the foregoing could have
adverse effects on our business, results of operations or financial condition.

Dependence of Single Product Line
---------------------------------

Concentration  of sales in a single product line for the medical health industry
represents a substantial risk, should market conditions deteriorate.

Foreign Currency
----------------

Our business plans are primarily focused on the penetration in the United States
and subsequently worldwide markets; therefore, we will be subject to the risk of
foreign currency fluctuations.

Competition and Sales Channels
------------------------------

Several  companies  compete  with us in the  syringe  market and there are a few
competitors  in the safety syringe  market.  Most are  substantially  larger and
possess greater  financial  resources than we do. Our future  success,  however,
relies on achieving superior product development by greater concentration on the
needs of the market and faster response to evolving customer requirements. There
can be no  assurance,  however,  that  competitors  will  not  develop  products
superior to our products or achieve greater market  acceptance due to marketing,
sales channels or other factors.

Dependence on Large Distributors
--------------------------------

We will rely in part on business  partners for the distribution of our products.
This includes a few large  distributors in the United States. We may be impacted
by negative business cycles or events  experienced by these  distributors.  This
may result in a short or long term reduction in revenue.

Human Resource Risks and Growth
-------------------------------

Our  success is  largely  dependent  on the  performance  of its key  employees.
Failure to attract and retain key employees with necessary  skills could have an
adverse  impact upon our growth and  profitability.  Our business is expected to
increase  rapidly  during the next three  years.  This  increase  will result in
substantial  growth in the number of  employees,  the scope of our operating and
financial systems and the geographic area of our operations.  This increases the
responsibilities for both existing and new management personnel.  Our ability to
support the  projected  growth of our  business  will be  dependent  upon having
highly  trained  personnel  in place to conduct  pre-sales  activities,  product
implementation and other customer support services. Our future operating results
will  depend on the ability of our key  managers  and  employees  to continue to
implement and improve our operational,  customer support and financial  systems.
There can be no  assurance  that we will be able to manage any future  expansion
successfully,  and, if we cannot, this could adversely affect the results of our
operations and our financial condition.



                                        6
<PAGE>



Changes in Number of Employees
------------------------------

During the next 12 months,  depending on the success of our  marketing  plan, we
may be  required  to hire  additional  employees;  however,  we are not  able to
provide a reasonable estimate of the number of such additional employees,  which
may be required at this time.

Production and Quality Control
------------------------------

The manufacturing of products involves a number of steps and requires compliance
with  stringent  quality  control   specifications  imposed  on  us  by  various
regulators.  We may not be able to replace manufacturing capacity quickly, if we
were unable to use our manufacturing  facilities as a result of a fire,  natural
disaster (including  earthquake),  equipment failure or other difficulty,  or if
such  facilities  are  deemed not in  compliance  with the  various  regulators'
requirements  and  the  non-compliance  could  not  be  rapidly  rectified.  The
inability or reduced  capacity to  manufacture or have  manufactured  any of our
products  would have a material  adverse  effect on the  business and results of
operations.

Government Standards and Regulations
------------------------------------

Our  products  will be subject to  numerous  foreign  government  standards  and
regulations  that are  continually  being amended.  Although we will endeavor to
satisfy foreign  technical and regulatory  standards,  there can be no assurance
that our products will comply with foreign government standards and regulations,
or changes  thereto,  or that it will be cost effective to redesign our products
to  comply  with such  standards  or  regulations.  Our  inability  to design or
redesign products to comply with foreign standards could have a material adverse
effect on our business, financial condition and results of operations.

Product Liability Risk
----------------------

Our  business  and the  business of our  subsidiary  will expose us to potential
product  liability  risks that are  inherent in the testing,  manufacturing  and
marketing  of medical  products.  We do not  currently  have  product  liability
insurance,  and  there  can be no  assurance  that we will be able to  obtain or
maintain such insurance on acceptable terms or, if obtained, that such insurance
will provide adequate coverage against potential liabilities.

We face an inherent  business  risk of exposure to product  liability  and other
claims,  in the event that the  development or use of our technology or products
is alleged to have  resulted  in adverse  effects.  That risk  exists  even with
respect to those  products  that are  manufactured  in  licensed  and  regulated
facilities or that otherwise  possess  regulatory  approval for commercial sale.
There can be no  assurance  that we will  avoid  significant  product  liability
exposure.  There can be no  assurance  that  insurance  will be available in the
future on commercially  reasonable terms, or at all, or that such insurance will
be  adequate  to pay  potential  product  liability  claims  or  that a loss  of
insurance  or the  assertion  of a product  liability  claim or claims would not
materially  adversely  affect our business,  financial  condition and results of
operations.

Although  we have  taken,  and  will  continue  to  take,  what we  believe  are
appropriate  precautions,   there  can  be  no  assurance  that  we  will  avoid
significant  liability  exposure.  An  inability  to  obtain  product  liability
insurance at acceptable cost or to otherwise  protect against  potential product
liability claims could prevent or inhibit the commercialization of our products.
A product  liability claim could have a material adverse effect on our business,
financial condition and results of operations.

Liquidity and Capital Resources
-------------------------------

We  believe we have  raised  enough  capital  to allow us to meet our  financial
obligations  for a period  of at least one  month  from  August  31,  2003,  not
including  our  current  obligations,  aggregating  $156,709  under the  British
Columbia Security Commission  rescission offer. However, this one-month forecast
is a  forward-looking  statement that involves risks and  uncertainties.  Actual
results could differ  significantly  as a result of these  uncertainties  as the
forecast  assumes  on-going  support from  creditors,  including the obligations
under the rescission offer, and shareholders.




                                        7
<PAGE>



We had cash resources of $6,536 at August 31, 2003. At May 31, 2003, we had cash
resources of $7,642.  On August 31, 2003,  total current  assets of were $81,236
and total current  liabilities were $643,833.  At August 31, 2003, total current
liabilities  exceeded total current assets by $562,597.  At May 31, 2003,  total
current assets were $98,859 and total current liabilities were $563,323.  At May
31, 2003, total current  liabilities  exceeded total current assets by $464,464.
Cash constitutes our current  internal sources of liquidity.  Because we are not
generating  any revenues  from the sale or licensing of our  products,  our only
external source of liquidity is the sale of our capital stock.

Management's plans include  generating future profitable  operations from future
sales of the retractable syringe as well as additional funding from stockholders
in the form of additional share subscriptions.  There can be no assurance that a
market  will  develop  for the  retractable  syringe  or that  additional  share
financings will be available or legally permissible.  Failure to obtain adequate
financing will cause the Company to curtail operations.

Critical Accounting Policies
----------------------------

The Company's  discussion and analysis of its financial condition and results of
operations,  including the  discussion on liquidity and capital  resources,  are
based upon the  Company's  financial  statements,  which have been  prepared  in
accordance with accounting  principles  generally accepted in the United States.
The  preparation  of these  financial  statements  requires  the Company to make
estimates and judgments that affect the reported amounts of assets, liabilities,
revenues  and  expenses,   and  related  disclosure  of  contingent  assets  and
liabilities.  On an ongoing  basis,  management  re-evaluates  its estimates and
judgments.  Actual results could differ from the estimates. The Company believes
the following critical accounting policy requires more significant  judgment and
estimates used in the preparation of the consolidated financial statements.

The  consolidated  financial  statements have been prepared on the going concern
basis, which assumes the realization of assets and liquidation of liabilities in
the normal course of operations.  If the Company were not to continue as a going
concern,  it  would  likely  not be able to  realize  on its  assets  at  values
comparable to the carrying  value or the fair value  estimates  reflected in the
balances set out in the preparation of the consolidated financial statements. As
described  elsewhere  in this  report,  at August  31,  2003  there are  certain
conditions that currently exist which raise substantial doubt about the validity
of this assumption.  While the Company  anticipates  raising  additional funding
through  future  profitable  operations and the sale of share  subscriptions  to
remove the  substantial  doubt,  these funds are not  assured.  Failure to raise
additional  funds may result in the  Company  curtailing  operations  or writing
assets and liabilities down to liquidation values, or both.

Results of Operations
---------------------

We have not yet realized any revenues from  operations.  The loss from March 17,
1997  (inception) to August 31, 2003, was  $5,113,977.  The loss for the 3-month
period ended August 31,  2003,  was $132,471  compared to a loss of $194,721 for
the 3-month period ended August 31, 2002.  Such losses were primarily the result
of product development and operational expenditures.

The current 3-month period loss has decreased  compared to the prior  comparable
period  because we are  restricting  outflow of funds  until we have  additional
capitalization.  During the 3-month  period ending August 31, 2003, we have paid
$22,898 with regards to developing the Syringe and the Blood  Collection  units,
compared to $23,103 incurred during the 3-months ending August 31, 2002. General
and  administrative  expenses for the 3-month  period ending August 31, 2003 was
$109,574,  compared to $171,892  incurred  during the 3-months ending August 31,
2002.

Item 3.  Controls and Procedures
--------------------------------

The company  maintains  disclosure  controls and procedures that are designed to
ensure that information  required to be disclosed in the Company's reports filed
pursuant to the  Securities  Exchange Act of 1934 are recorded,  processed,  and
summarized and reported within the time periods specified in the rules and forms
promulgated  under  such  Act,  and that such  information  is  accumulated  and
communicated to the Company's management,  including the Chief Executive Officer
and Chief Financial Officer, as appropriate, to allow timely decisions regarding
required disclosure.


                                        8
<PAGE>




Within  the 90 days  prior  to the  date of this  report,  the  Company's  Chief
Executive Officer and Chief Financial  Officer,  with the participation of other
members of  management,  carried out an evaluation of the  effectiveness  of the
design  and  operation  of the  Company's  disclosure  controls  and  procedures
pursuant to Exchange  Act Rule 13a-14 of the  Securities  Exchange  Act of 1934.
Based upon that  evaluation,  the Chief  Executive  Officer and Chief  Financial
Officer  concluded that the disclosure  controls and procedures are effective in
connection  with the  filing of this  Quarterly  Report on Form  10-QSB  for the
quarter ended August 31, 2003.

There were no significant changes in the Company's internal controls or in other
factors that could significantly affect these controls subsequent to the date of
our most recent evaluation,  including any significant deficiencies and material
weaknesses of internal controls that would require corrective action.










































                                        9
<PAGE>



                                     Part II
                                     -------


Item 1.  Legal Proceedings
--------------------------

Litigation Involving Our Subsidiary.
------------------------------------

None

British Columbia Securities Commission.
---------------------------------------

During the year ended May 31 2002, the Company engaged in discussions with staff
of the British  Columbia  Securities  Commission  (the  "BCSC")  concerning  the
distribution  of the  Company's  common  stock to certain  residents  of British
Columbia.  Staff of the BCSC took the position that the  distribution of certain
shares may not have, in all  circumstances,  satisfied the prospectus  exemption
requirements  under the Securities Act (British  Columbia).  In order to resolve
the  concerns  of staff of the  BCSC,  the  Company  agreed  to make an offer of
rescission (the  "Rescission  Offer") to purchasers of its common stock residing
in British  Columbia.  Stockholders  who acquired  99,933 common shares from the
Company for aggregate  proceeds of $263,573 exercised their right of rescission.
As of Aug 31, 2003, the Company has repaid $47,851 of the $263,573. In addition,
during  the year ended May 31,  2003,  32,363  shares  were  retracted  from the
rescission offer by the original purchaser, resulting in a decrease in liability
of $59,013.  These  shares were  returned to the  shareholder  and removed  from
treasury  stock.  The  remaining  payable  balance of  $156,709  is  included in
accounts payable and accrued liabilities on the consolidated  balance sheet. The
Company does not have sufficient funds to repay this liability at this time.

As of Aug 31, 2003, three  shareholders,  not entitled to the rescission  offer,
holding 1,000, 2,205, and 1,000 common shares with a cost of $1,000, $6,851, and
$3,250  respectively,  requested  that the  Company  accept  the return of their
shares.  The Company  accepted  the return of the shares and repaid the original
subscription  price of $1,000 to one shareholder and has recorded a liability of
$10,101,  which is included in accounts payable and accrued  liabilities for the
other shareholder.  All of these shares are held as treasury stock as at Aug 31,
2003.

The  Company  and John  Klippenstein  appeared  in a hearing  before the BCSC on
October  9,  2003 to  respond  to  various  allegations  and the  status  of the
rescission  offer (note 2(a)).  Possible  implications  of the  hearing,  if the
ruling  is not in favour  of John  Klippenstein  and the  Company,  include  Mr.
Klippenstein  and the Company  being banned from trading  securities  in British
Columbia,  Mr.  Klippenstein  being  banned from being a director or engaging in
investor relations activities and the payment of penalties,  fines and the costs
of the hearing.  The Company and John  Klippenstein  dispute the validity of the
allegations, consulted legal counsel, and intend to vigorously defend themselves
against the  allegations.  The outcome of these matters  cannot be determined at
this time.

There are no other security issues pending against the Company nor are any other
such actions contemplate.












                                       10
<PAGE>




Item 2.  Changes in Securities
------------------------------

Warrants.
---------

We have offered to all  shareholders of record at June 30, 2001, one warrant for
every 2 shares held by each  shareholder.  Each  warrant  entitles the holder of
such warrant to purchase one share of our common stock for $5.00 per share. Each
warrant  expires 90 days after the first  transaction in our common stock occurs
on a public market

Stock Options.
--------------

Our Board of Directors  has adopted a stock option plan ("Stock  Option  Plan").
The Stock Option Plan is designed to retain  qualified and  competent  officers,
employees and directors of the Company.  Our Board of Directors,  or a committee
thereof,  shall administer the Stock Option Plan and is authorized,  in its sole
and absolute  discretion,  to grant  options to all of our  eligible  employees,
officers and  directors  (whether or not employed by us).  During the year ended
May 31, 2001,  340,417 and during the nine month period ended February 28, 2003,
359,833  stock  options were granted in  accordance  with the Stock Option Plan.
Under  SFAS 123,  compensation  cost of  $486,719  has been  recorded  for those
options issued to consultants to August 31, 2003.  Options  granted  pursuant to
the Stock  Option Plan will be  exercisable  within the period  specified in the
respective stock option agreements.  Options granted under the Stock Option Plan
will not be exercisable  after the expiration of ten (10) years from the date of
grant  for  shareholders  with less  than 10%  ownership  and five (5) years for
shareholders with 10% or more share ownership.

Share Issuances.
----------------

During the three  months  ended  August 31,  2003,  there were no common  shares
issued pursuant to Regulation S.

Item 3.  Default Upon Senior Securities
---------------------------------------

None.

Item 4.  Submission of Matters to Vote of Security Holders
----------------------------------------------------------

None

Item 5.  Other Information
--------------------------

This quarterly reporting, including consolidated financial statements for August
31, 2003 and the management's report, have not been reviewed by the auditors' of
the Company.  The auditors' of the Company are currently performing a review and
the Company will file an amendment to the August 31, 2003 10-QSB filing once the
review is complete.

Item 6.  Exhibits and Reports on Form 8-K
-----------------------------------------

Effective  September 5, 2003,  the Board of  Director's  appointed  Mr.  Anthony
Hawkshaw as a Director.  Effective  September 5, 2003,  the Board of  Director's
appointed Mrs. Maria  Klippenstein as a Director.  Effective  September 5, 2003,
the Board of Director's  appointed Mr. Lionel  Mathews as a Director.  Effective
October 8, 2003,  the Board of Director's  appointed  Mr.  Darren  McGregor as a
Director.









                                       11
<PAGE>




                                   SIGNATURES
                                   ----------

Pursuant  to the  requirements  of the  Securities  Exchange  Act of  1934,  the
Registrant  has duly  caused  this  report  to be  signed  on its  behalf by the
undersigned thereunto duly authorized.

Dated:  October 10, 2003                      L.O.M. Medical International, Inc.


                                        By:   /s/ John Klippenstein
                                              -------------------------------
                                              John Klippenstein
                                        Its:  President


                                        By:   /s/ Tanya Sedlacek
                                              -------------------------------
                                              Tanya Sedlacek
                                        Its:  Chief Financial Officer




































                                       12
<PAGE>



                                 CERTIFICATIONS
                                 --------------

I, John Klippenstein, certify that:

1.   I have  reviewed  this  quarterly  report on Form 10-QSB of L.O.M.  Medical
International Inc.;

2.   Based on my knowledge,  this  quarterly  report does not contain any untrue
statement of a material fact or omit to state a material fact  necessary to make
the statements made, in light of the  circumstances  under which such statements
were made, not  misleading  with respect to the period covered by this quarterly
report;

3.   Based on my  knowledge,  the  financial  statements,  and  other  financial
information  included in this quarterly  report,  fairly present in all material
respects the financial  condition,  results of operations  and cash flows of the
registrant as of, and for, the periods presented in this quarterly report;

4.   The  registrant's  other  certifying  officer  and  I are  responsible  for
establishing and maintaining  disclosure  controls and procedures (as defined in
Exchange Act Rules 13a-14 and 15d-14) for the registrant and we have:

     c)   designed  such  disclosure  controls  and  procedures  to ensure  that
          material  information  relating  to  the  registrant,   including  its
          consolidated subsidiaries,  is made known to us by others within those
          entities,  particularly  during  the  period in which  this  quarterly
          report is being prepared;

     d)   evaluated the  effectiveness of the registrant's  disclosure  controls
          and procedures as of a date within 90 days prior to the filing date of
          this quarterly report (the "Evaluation Date"); and

     e)   presented  in  this  quarterly   report  our  conclusions   about  the
          effectiveness  of the disclosure  controls and procedures based on our
          evaluation as of the Evaluation Date;

5.   The registrant's  other certifying  officer and I have disclosed,  based on
our most recent evaluation, to the registrant's auditors and the audit committee
of the  registrant's  board of directors (or persons  performing  the equivalent
function):

     c)   all  significant  deficiencies  in the design or operation of internal
          controls  which could  adversely  affect the  registrant's  ability to
          record,  process,   summarize  and  report  financial  data  and  have
          identified for the  registrant's  auditors any material  weaknesses in
          internal controls; and

     d)   any fraud, whether or not material,  that involves management or other
          employees who have a  significant  role in the  registrant's  internal
          controls; and

6.   The  registrant's  other  certifying  officer and I have  indicated in this
quarterly  report  whether or not there  were  significant  changes in  internal
controls or in other factors that could  significantly  affect internal controls
subsequent to the date of our most recent  evaluation,  including any corrective
actions with regard to significant deficiencies and material weaknesses.


Date: October 10, 2003



/s/ John Klippenstein
----------------------------------------
John Klippenstein, President & CEO





                                       13
<PAGE>



                                 CERTIFICATIONS
                                 --------------

I, Tanya Sedlacek, certify that:

7.   I have  reviewed  this  quarterly  report on Form 10-QSB of L.O.M.  Medical
International Inc.;

8.   Based on my knowledge,  this  quarterly  report does not contain any untrue
statement of a material fact or omit to state a material fact  necessary to make
the statements made, in light of the  circumstances  under which such statements
were made, not  misleading  with respect to the period covered by this quarterly
report;

9.   Based on my  knowledge,  the  financial  statements,  and  other  financial
information  included in this quarterly  report,  fairly present in all material
respects the financial  condition,  results of operations  and cash flows of the
registrant as of, and for, the periods presented in this quarterly report;

10.  The  registrant's  other  certifying  officer  and  I are  responsible  for
establishing and maintaining  disclosure  controls and procedures (as defined in
Exchange Act Rules 13a-14 and 15d-14) for the registrant and we have:

     c)   designed  such  disclosure  controls  and  procedures  to ensure  that
          material  information  relating  to  the  registrant,   including  its
          consolidated subsidiaries,  is made known to us by others within those
          entities,  particularly  during  the  period in which  this  quarterly
          report is being prepared;

     d)   evaluated the  effectiveness of the registrant's  disclosure  controls
          and procedures as of a date within 90 days prior to the filing date of
          this quarterly report (the "Evaluation Date"); and

     e)   presented  in  this  quarterly   report  our  conclusions   about  the
          effectiveness  of the disclosure  controls and procedures based on our
          evaluation as of the Evaluation Date;

11.  The registrant's  other certifying  officer and I have disclosed,  based on
our most recent evaluation, to the registrant's auditors and the audit committee
of the  registrant's  board of directors (or persons  performing  the equivalent
function):

     c)   all  significant  deficiencies  in the design or operation of internal
          controls  which could  adversely  affect the  registrant's  ability to
          record,  process,   summarize  and  report  financial  data  and  have
          identified for the  registrant's  auditors any material  weaknesses in
          internal controls; and

     d)   any fraud, whether or not material,  that involves management or other
          employees who have a  significant  role in the  registrant's  internal
          controls; and

12.  The  registrant's  other  certifying  officer and I have  indicated in this
quarterly  report  whether or not there  were  significant  changes in  internal
controls or in other factors that could  significantly  affect internal controls
subsequent to the date of our most recent  evaluation,  including any corrective
actions with regard to significant deficiencies and material weaknesses.


Date: October 10, 2003



/s/ Tanya Sedlacek
----------------------------------------
Tanya Sedlacek, CFO




                                       14